Age, year
|
52.1 ± 11.6
|
53.3 ± 11.7
|
0.082
|
Gender, male/female
|
332 (85.3%)/57 (14.7%)
|
973 (84.5%)/178 (15.5%)
|
0.700
|
Hepatitis B history, yes/no
|
317 (83.6%)/62 (16.4%)
|
938 (83.0%)/192 (17.0%)
|
0.776
|
ALT, U/L
|
54.4 ± 84.7
|
50.7 ± 64.6
|
0.370
|
γ-GT, U/L
|
94.3 ± 84.9
|
86.9 ± 92.7
|
0.168
|
Albumin, g/L
|
40.9 ± 4.9
|
41.6 ± 4.6
|
0.010
|
Liver cirrhosis, yes/no
|
312 (81.0%)/73 (19.0%)
|
956 (84.3%)/178 (15.7%)
|
0.153
|
α-Fetoprotein (>200/≤200 ng/dL)
|
191 (49.1%)/198 (50.9%)
|
402 (34.9%)/749 (65.1%)
|
<0.001
|
Tumor size, cm
|
6.5 ± 3.8
|
4.9 ± 3.3
|
<0.001
|
Tumor size (>5 cm/≤5 cm)
|
195 (50.1%)/194 (49.9%)
|
370 (32.1%)/781 (67.9%)
|
<0.001
|
Tumor number, solitary/multiple
|
332 (85.3%)/57 (14.7%)
|
1009 (87.7%)/142 (12.3%)
|
0.239
|
Tumor encapsulation, complete/no
|
166 (42.9%)/221 (57.1%)
|
637 (55.4%)/512 (44.6%)
|
<0.001
|
Tumor differentiation, I–II/III–IV
|
232 (59.9%)/155 (40.1%)
|
866 (76.5%)/266 (23.5%)
|
<0.001
|
BCLC stage, 0/A/B
|
24 (6.2%)/312 (80.2%)/53 (13.6%)
|
170 (14.8%)/880 (76.5%)/101 (8.8%)
|
<0.001*
|